Clinical Trial News and Research

RSS

Fibrogen reports FG-3019 Phase 2 study results for treatment of pancreatic cancer

FibroGen, Inc. today announced results from a Phase 2 open-label study of FG-3019, an investigational anti-fibrotic antibody, in combination with gemcitabine and erlotinib for the treatment of patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).

31 May 2014

ASCO: Biothera to present phase 2 study data on predictive serum biomarker for NSCLC

Biothera will present research at the American Society of Clinical Oncology annual meeting linking a potential predictive serum biomarker to the clinical response to Imprime PGG immunotherapy in a recent phase 2 study in non-small cell lung cancer patients. The meeting begins today and runs through June 3 in Chicago.

31 May 2014

Amgen presents extended analysis of PEAK study data at ASCO

Amgen today announced results from the Phase 2 PEAK study that reinforce the improved overall survival (OS) benefit of panitumumab (Vectibix®) when used in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, compared to bevacizumab (Avastin) plus FOLFOX as first-line treatment in patients with wild-type RAS metastatic colorectal cancer (mCRC).

31 May 2014

Goserelin can help reduce risk of early menopause in young women with breast cancer

Among young women treated for breast cancer, one of the most distressing side effects of chemotherapy is early menopause.

31 May 2014

Mount Sinai Heart to host four-day symposium on Complex Coronary, Valvular, and Vascular Cases

Mount Sinai Heart will host its innovative and prestigious 17th Annual 2014 Live Symposium of Complex Coronary, Valvular, and Vascular Cases June 10-13 at The Mount Sinai Hospital.

31 May 2014

Forest publishes data from pivotal Phase III Study of Investigational FDC of nebivolol and valsartan

Forest Laboratories, Inc. (NYSE:FRX) today announced the publication of data from its pivotal Phase III Study of an Investigational Fixed-Dose Combination (FDC) of nebivolol and valsartan in the May 30, 2014 issue of The Lancet.

31 May 2014

$ASCO: DelMar presents interim data from VAL-083 clinical trial in refractory GBM$

ASCO: DelMar presents interim data from VAL-083 clinical trial in refractory GBM

DelMar Pharmaceuticals, Inc. announced the presentation of interim clinical data from the company's ongoing clinical trial with VAL-083 in refractory glioblastoma multiforme (GBM) during the Central Nervous System Tumor Session at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), which is being held at the McCormick Place Convention Center in Chicago.

31 May 2014

Eisai announces results from Phase III SELECT trial of lenvatinib evaluating PFS in patients with RR-DTC

Eisai Inc. announced today results from the Phase III SELECT trial of investigational agent lenvatinib evaluating progression-free survival (PFS) in patients with progressive radioiodine-refractory differentiated thyroid cancer (RR-DTC).

31 May 2014

New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

Boehringer Ingelheim today announced that new data will be presented from 7 abstracts for Gilotrif (afatinib) and investigational compounds, including nintedanib and BI 836845, from its oncology pipeline at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, on May 30 – June 3, 2014.

31 May 2014

CIRM grants $5.6 million to develop HIV/AIDS therapeutic using Sangamo's ZFN genome-editing technology

Sangamo BioSciences, Inc. announced that the California Institute for Regenerative Medicine (CIRM) has granted a $5.6 million Strategic Partnership Award to fund clinical studies at City of Hope to develop a potentially curative ZFP Therapeutic for HIV/AIDS based on the application of Sangamo's zinc finger nuclease (ZFN) genome-editing technology in hematopoietic stem/progenitor cells (HSPCs).

31 May 2014

Promedior reports positive preliminary data from PRM-151 Phase 2 trial for myelofibrosis

Promedior, Inc., today announced positive preliminary data from its Phase 2 trial of PRM-151, an anti-fibrotic immunotherapy, in patients with myelofibrosis which demonstrated biologic activity with improvements across clinically relevant measures, including bone marrow fibrosis, hemoglobin, platelets, spleen, and symptoms.

31 May 2014

Angiochem presents data on ANG1005 paclitaxel-peptide drug conjugate at 50th ASCO annual meeting

Angiochem, a clinical stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB), today announced the presentation of data for its lead drug candidate, ANG1005, a novel paclitaxel-peptide drug conjugate, at the American Society of Clinical Oncology 50th Annual Meeting in Chicago, IL.

31 May 2014

ArQule to present tivantinib clinical trial data at ASCO 2014

ArQule, Inc. today announced that tivantinib will be included in seven presentations during the 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held from May 30, 2014 to June 3, 2014 in Chicago, Illinois.

31 May 2014

Deciphera initiates altiratinib MET/TIE2/VEGFR/TRK kinase inhibitor Phase 1 trial for solid tumors

Deciphera Pharmaceuticals, a clinical stage biotechnology company focused on improved kinase inhibitor treatments for cancer, today announced the initiation of a Phase 1 clinical trial of its MET/TIE2/VEGFR2/TRK inhibitor altiratinib (DCC-2701).

31 May 2014

OSU/UH receive $7.5M grant to study slow progression of myopia in kids

The University of Houston (UH) is part of a National Institutes of Health (NIH) study to determine whether commercially available, soft bifocal contact lenses slow the progression of nearsightedness in children.

30 May 2014

Viewpoints: Michelle Obama and school lunches; more about the VA health system 'scandal'; context and caution on Medicare's physician data release

When we began our Let's Move! initiative four years ago, we set one simple but ambitious goal: to end the epidemic of childhood obesity in a generation so that kids born today will grow up healthy.

30 May 2014

Active Implants receives IDE approval to conduct NUsurface Meniscus Implant trial for knee osteoarthritis

Active Implants, the technology leader in cushion-bearing orthopedics for treatment of osteoarthritis, today announced it has received Investigational Device Exemption (IDE) approval to conduct a pivotal clinical trial of the NUsurface® Meniscus Implant in patients with knee osteoarthritis.

30 May 2014

Study reveals how BTK mutation triggers drug resistance in CLL patients

A multi-institutional team of researchers has pinpointed exactly what goes wrong when chronic lymphocytic leukemia (CLL) patients develop resistance to ibrutinib, a highly effective, precisely targeted anti-cancer drug.

29 May 2014

Synexus starts new state of art clinical trial centre in Bochum, Germany

On 28th May, 2014, Synexus officially opened a new state of the art clinical trial centre in Bochum, Germany.

From AES - Accelerated Enrollment Solutions 29 May 2014

Study shows high BP drugs may raise likelihood of age-related macular degeneration

There may be a connection between taking vasodilators and developing early-stage age-related macular degeneration (AMD), the leading cause of vision loss and blindness among Americans who are age 65 and older, according to a study published online in Ophthalmology, the journal of the American Academy of Ophthalmology.

29 May 2014

Clinical Trial News and Research

Fibrogen reports FG-3019 Phase 2 study results for treatment of pancreatic cancer

ASCO: Biothera to present phase 2 study data on predictive serum biomarker for NSCLC

Amgen presents extended analysis of PEAK study data at ASCO

Goserelin can help reduce risk of early menopause in young women with breast cancer

Mount Sinai Heart to host four-day symposium on Complex Coronary, Valvular, and Vascular Cases

Forest publishes data from pivotal Phase III Study of Investigational FDC of nebivolol and valsartan

ASCO: DelMar presents interim data from VAL-083 clinical trial in refractory GBM

Eisai announces results from Phase III SELECT trial of lenvatinib evaluating PFS in patients with RR-DTC

New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

CIRM grants $5.6 million to develop HIV/AIDS therapeutic using Sangamo's ZFN genome-editing technology

Promedior reports positive preliminary data from PRM-151 Phase 2 trial for myelofibrosis

Angiochem presents data on ANG1005 paclitaxel-peptide drug conjugate at 50th ASCO annual meeting

ArQule to present tivantinib clinical trial data at ASCO 2014

Deciphera initiates altiratinib MET/TIE2/VEGFR/TRK kinase inhibitor Phase 1 trial for solid tumors

OSU/UH receive $7.5M grant to study slow progression of myopia in kids

Viewpoints: Michelle Obama and school lunches; more about the VA health system 'scandal'; context and caution on Medicare's physician data release

Active Implants receives IDE approval to conduct NUsurface Meniscus Implant trial for knee osteoarthritis

Study reveals how BTK mutation triggers drug resistance in CLL patients

Synexus starts new state of art clinical trial centre in Bochum, Germany

Study shows high BP drugs may raise likelihood of age-related macular degeneration

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer